Drugs / LACTIN-V
LACTIN-V
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03992534 | Sep 2019 → Oct 2021 | cervical incompetence, habitual spontaneous abortion, preterm premature rupture of the membranes | Imperial College London | Unknown | No outcome recorded |
| Phase 1 | NCT00537576 | Nov 2007 → Mar 2008 | bacterial vaginosis | Osel, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02766023 | Jun 2016 → Feb 2019 | bacterial vaginosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00635622 | Apr 2008 → Jan 2009 | bacterial vaginosis | Osel, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00305227 | Mar 2006 → Apr 2012 | urinary tract infection | University of Washington | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05022212 Comparator | May 2021 → Mar 2023 | HIV infectious disease, bacterial vaginosis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT05166746 Comparator | Dec 2017 → Oct 2023 | bacterial vaginosis, female infertility | Peter Humaidan | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03151967 Comparator | Sep 2015 → Apr 2017 | urinary tract infection | University of Washington | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LACTIN-V | “METHODS: A phase 2a study assessed colonization efficiency, safety, tolerability, and acceptability of Lactobacillus crispatus CTV-05 (LACTIN-V) administered by a vaginal applicator.” PMID 20644497 ↗ Dec 20106“Oral Clindamycin 300 mg 2 times per day for 7 days followed by LACTIN-V (Osel, Inc.) until completion of the clinical pregnancy scan at week 7-9.” NCT05166746 ↗ “LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator.” NCT02766023 ↗ “Name of Product: LACTIN-V (Lactobacillus crispatus CTV-05)” NCT03992534 ↗ |
| Known as | CTV-05 | “METHODS: A phase 2a study assessed colonization efficiency, safety, tolerability, and acceptability of Lactobacillus crispatus CTV-05 (LACTIN-V) administered by a vaginal applicator.” PMID 20644497 ↗ Dec 2010 |
| Known as | Lactobacillus crispatus CTV-05 | “METHODS: A phase 2a study assessed colonization efficiency, safety, tolerability, and acceptability of Lactobacillus crispatus CTV-05 (LACTIN-V) administered by a vaginal applicator.” PMID 20644497 ↗ Dec 20103“Name of Product: LACTIN-V (Lactobacillus crispatus CTV-05)” NCT03992534 ↗ |
| Modality | Other / unclassified | “this "probiotic" to be safe and well tolerated.” NCT00305227 ↗ |
| Route | Other | “LACTIN-V administered vaginally” NCT00635622 ↗ |